Contact Information: Contact: digiMedical Solutions, Inc. Investor Relations ir@digimedical.com 214-722-3029
digiMedical Solutions, Inc.(TM) Signs Contract With John P. Landi, M.D., Medical Director of Vanish Vein and Laser Center in Naples, Florida, in Support of $10 Million 2008 Revenue Goal
Contract Follows Recent Sales Expansion in Florida Markets
| Source: digiMedical Solutions, Inc.
COLLEYVILLE, TX--(Marketwire - March 27, 2008) - digiMedical Solutions, Inc. (PINKSHEETS : DGMS ) announced today that the Company has signed a contract with John P.
Landi, M.D., Medical Director of Vanish Vein and Laser Center in Naples,
Florida, to implement the digiRX system and digiReauth call center
services. The system and services will provide digital prescription
handling for Dr. Landi's office and will take over the prescription
reauthorization processing and refill management services. This contract
follows digiMedical's recent announcement of increasing the sales team in
the Naples and Fort Myers, Florida, markets to expand the Company's
regional footprint and support the Company's $10 million 2008 revenue goal.
Dr. Landi stated, "The digiRX digital prescription handling system will
help protect us against prescription fraud. Recently we have seen several
instances in which patients altered the quantity in their prescriptions.
digiRX will protect us from forged prescriptions and clear up much of the
malpractice risk associated with patients doing this. Also, the digiReauth
system will help reduce the amount of phone calls to our office, so nurses
will have more face-time for patients."
digiMedical Solutions, a Microsoft Partner, with operations in Texas and
Florida, has built its own suite of proprietary software to handle
prescriptions digitally from the physician's office to the pharmacy,
securely and in compliance with all DEA and HIPAA requirements. The suite
of software includes digiRX, digiRxStream, digiReauth, digiRxComp, and now
digiAccounting and the Company owns and operates five pharmacies throughout
Texas and Florida.
Company Information and Updates
To be added to digiMedical's corporate e-mail list for shareholders and
interested investors or to receive more information on the company, please
send an e-mail to ir@digimedical.com.
About Vanish Vein and Laser Center (http://www.vanishvein.com/about.cfm)
Vanish Vein and Laser Center, located in Naples, FL, is a state of the art
Vein Center established in 2002, dedicated to the complete eradication of
unwanted veins anywhere in the body, from varicose and spider veins in the
legs to unsightly veins on the hands, body and face. Modalities of
treatment include laser vein ablation, venous closure, percutaneous
ultrasonic directed sclerotherapy, foam sclerotherapy as well as
microphlebectomies and venous stasis ulcer treatment.
About digiMedical Solutions, Inc.™
digiMedical Solutions, Inc.™ (www.digimedical.com) is a pharmacy and
medical technology company focused on developing next generation digital
medical technology with an emphasis on digital prescriptions
(d-prescriptions) that will more closely align the doctor, pharmacist and
patient. The company's planned growth will come from three channels: direct
marketing of the company's wireless base d-prescription technology to
doctors, acquisition of independent pharmacy chains and the sale of certain
territories to "market partners" licensed to exploit the digiMedical
Solutions™ model. digiMedical Solutions, Inc.™ currently owns and
operates five (5) pharmacies located in Texas and Florida. digiMedical
Solutions™' unique business model brings doctor, patients and pharmacies
into next generation medical technologies.
Forward-Looking Statement
Statements included in this press release which are not historical in
nature, are intended to be, and are hereby identified as "Forward-Looking
Statements" for purposes of safe harbor provided by Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-Looking Statements may
be identified by words including "anticipate," "await," "envision,"
"foresee," "aim at," "believe," "intends," "estimates" including without
limitation, those relating to the company's future business prospects, are
subject to certain risks and uncertainties that could cause actual results
to differ materially from those indicated in the Forward-Looking
Statements. Readers are directed to the company's filings with the U.S.
Securities and Exchange Commission for additional information and a
presentation of the risks and uncertainties that may affect the company's
business and results of operations.